![John E. Lucas](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Bob Cook | M | 68 |
EpiCept Corp.
![]() EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | 9 years |
Dirk van den Boom | M | 53 | 18 years | |
Hubert Köster | M | - | 4 years | |
John V. Talley | M | 68 |
EpiCept Corp.
![]() EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | 11 years |
Antonius P. Schuh | M | 59 | 5 years | |
Dov Elefant | M | 56 |
EpiCept Corp.
![]() EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | 8 years |
Ronald M. Lindsay | M | 76 | 13 years | |
Harry Hixson | M | 84 | 12 years | |
Harry Stylli | M | 62 | 4 years | |
Robin M. Jackman | M | 54 | - | |
Dileep Bhagwat | M | 73 |
EpiCept Corp.
![]() EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | 8 years |
John P. Sharp | M | 59 | 3 years | |
Frank V. Esser | M | 84 | - | |
Shishir Sinha | M | 57 | 3 years | |
Fareed Kureshy | M | 81 | 2 years | |
Charlie Rodi | M | - | 3 years | |
Sudipto Sur | M | - | 3 years | |
Jeffrey Otto | M | - | - | |
Helmut Schühsler | M | 65 | 7 years | |
Larry M. Myres | M | 65 | - | |
Gert August Paul Caspritz | M | 74 |
EpiCept Corp.
![]() EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | 9 years |
Jay Lichter | M | 62 | - | |
Jerome Mahoney | M | 64 | 3 years | |
Stephen L. Zaniboni | M | 65 | 8 years | |
Dan Kisner | M | 77 | - | |
Dereck A. Tatman | M | 51 | - | |
Karsten Schmidt | M | 62 | - | |
Clarke Neumann | M | 60 | 15 years | |
Michael J. Terry | M | 69 | 2 years | |
Tristan B. Orpin | M | 58 | 3 years | |
Mathias Ehrich | M | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 31 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John E. Lucas
- Personal Network